Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midodrine + octreotide
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Midodrine + octreotide is a combination therapy used primarily in the management of hepatorenal syndrome (HRS), particularly types 1 and 2. Midodrine is an alpha-1 adrenergic agonist that increases systemic vascular resistance and blood pressure, while octreotide is a somatostatin analogue that suppresses splanchnic vasodilation. Together, they are often administered with albumin to improve renal perfusion and function in patients with advanced liver disease[1][2][4]. This combination has been shown to improve short-term survival and renal function in HRS patients, serving as a bridge to liver transplantation or preventing progression of HRS type 2 to HRS type 1[1][2].
- Other names
- midodrine and octreotideoctreotide/midodrine
02
Targets
ADRA1A (α1A)SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on midodrine + octreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midodrine + octreotide.